Frontline Management of Atopic Dermatitis in Adults - Episode 15
Evaluation of Long-Term Data With JAK Inhibitors
Panelists discuss how the JADE EXTEND study (Shi 2022) found that most patients who achieved EASI-75 with dupilumab also responded to abrocitinib. Even some dupilumab nonresponders achieved EASI-75. Adverse events (AEs) included nausea, acne, and headache.
Video content above in prompted by the following:
- The JADE EXTEND study looked at abrocitinib use in patients who had previously taken dupilumab (Shi 2022). In your experience, does a patient’s positive response to one therapeutic suggest they will also be responsive to a different therapeutic? Similarly, do you find that nonresponders to one therapeutic also are nonresponders to other therapeutics?
- In patients who achieved an EASI-75 response with dupilumab, 83/92 (90.2%) achieved EASI-75 with 100 mg abrocitinib and 43/46 (93.5%) achieved EASI-75 with 200 mg abrocitinib after 12 weeks.
- In patients who did not achieve an EASI-75 response with dupilumab, 21/31 (67.7%) achieved EASI-75 with 100 mg abrocitinib and 16/20 (80.0%) achieved EASI-75 with 200 mg abrocitinib after 12 weeks.
- AEs included nasopharyngitis, nausea, acne, and headache.
